Characterization and Evaluation of Newly Developed Immune-Chromatographic Method Targeting Mycoplasma pneumoniae Ribosomal Protein L7/L12.

Characterization and Evaluation of Newly Developed Immune-Chromatographic Method Targeting Mycoplasma pneumoniae Ribosomal Protein L7/L12. J Med Microbiol. 2016 Aug 19; Authors: Sano G, Itagaki T, Ishiwada N, Matsubara K, Iwata S, Nakamori Y, Matsuyama K, Watanabe K, Ishii Y, Homma S, Tateda K Abstract Point-of-care testing (POCT) for Mycoplasma pneumoniae infection may be ideal and useful, because significant numbers of the cases will be seen as an outpatient. Recently, a new immune-chromatographic method (ICM) targeting M. pneumoniae ribosomal protein L7/L12 (RP-L7/L12) became available in Japan, although clinical data and basic information regarding efficacy and characterization of this ICM are limited. The present study examined the fate of M. pneumoniae ribosomal protein L7/L12 (RP-L7/L12) during the growth in-vitro and correlation between M. pneumoniae number in clinical samples and positivity in RP-L7/L12 ICM. Also, usefulness of RP-L7/L12 ICM was investigated in 176 pharyngeal swabs from M. pneumoniae infection-suspected patients (children 137 cases; adults 39 cases). In-vitro analysis, the detection limit was shown to be 1.1 × 104 CFU/mL for M. pneumoniae. Production of RP-L7/L12 was paralleled with viable M. pneumoniae number, and a half-life was calculated to be approximately 2 days in-vitro. Five other Mycoplasma species and 14 representative respiratory pathogens exhibited negative even in a concentration of 106 CFU/mL....
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research